Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 6
Submit an article Journal homepage
287
Views
3
CrossRef citations to date
0
Altmetric
Letter to the Editor

Central nervous system relapse in patients with diffuse large B-cell lymphoma: analysis of incidence and prognostic factors

Masahiro UniDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
,
Yuki KagoyaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
,
Yasuhito NannyaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
,
Fumihiko NakamuraDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
&
Mineo KurokawaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan;Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital, Tokyo, JapanCorrespondence[email protected]
Pages 1869-1871 | Received 02 Jun 2014, Accepted 21 Sep 2014, Published online: 05 Nov 2014

References

  • Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
  • Trneny M, Rieger M, Osterborg A, et al. The addition of rituximab eliminates the negative prognostic impact of PMBCL compared to DLBCL in young patients with CD20-positive aggressive lymphomas receiving a CHOP-like chemotherapy: results of a subgroup analysis of the Mabthera International Trial Group (MInT) study. Blood 2008; 112 (Suppl. 1): Abstract 839.
  • Bokstein F, Lossos A, Lossos IS, et al. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma 2002;43:587–593.
  • Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol 2013;31:3971–3979.
  • Martín A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO Study Haematologica 2008;93:1829–1836.
  • Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496–509.
  • Villa D, Connors JM, Shenkier TN, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 2010;21:1046–1052.
  • Boehme V, Schmitz N, Zeynalova S, et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009;113:3896–3902.
  • Bernstein SH, Unger JM, Leblanc M, et al. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 – the Southwest Oncology Group. J Clin Oncol 2009;27:114–119.
  • Tomita N, Yokoyama M, Yamamoto W, et al. Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 2012;103:245–251.
  • Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol 2011;90:809–818.
  • Wilson WH, Bromberg JE, Stetler-Stevenson M, et al. Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica 2014;99: 1228–1235.
  • Guirguis HR, Cheung MC, Mahrous M, et al. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. Br J Haematol 2012;159:39–49.
  • Avilés A, Jesús Nambo M, Neri N. Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: an analysis of 3,258 patients in a single center. Med Oncol 2013;30:520.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.